Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment

Epilepsia ◽  
2022 ◽  
Author(s):  
Virginia Pironi ◽  
Ornella Ciccone ◽  
Ettore Beghi ◽  
Hazel Paragua‐Zuellig ◽  
Archana A. Patel ◽  
...  
Keyword(s):  
Task Force ◽  
Access To Treatment

scholarly journals Addressing the Opioid Crisis through an Interdisciplinary Task Force in Cincinnati, Ohio, USA

Pharmacy ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 116
Author(s):  
Neil J MacKinnon ◽  
Ellena Privitera
Keyword(s):  
Local Governments ◽  
Task Force ◽  
The United States ◽  
Opioid Use Disorder ◽  
Opioid Use ◽  
Access To Treatment ◽  
Opioid Crisis ◽  
Comprehensive Health ◽  
Recovery Resources ◽  
State And Local

Opioid use has been a topic of concern in recent years in the United States, causing thousands of deaths each year. Ohio is one of the states hit hardest by the epidemic, and its state and local governments have responded with comprehensive health policies. Cincinnati, located in the southwest region of Ohio, is one of the epicenters of the state’s opioid crisis. Responding to the needs of their community, the University of Cincinnati (UC) and its affiliate health system, UC Health, have brought together leaders in research, clinical practice, and education to form the UC/UC Health Opioid Task Force. By encouraging interdisciplinary partnerships, the Task Force is pioneering new ways to understand, prevent, and treat opioid use disorder, while preparing the next generation of healthcare professionals. Additionally, collaboration across departments in UC Health has improved access to treatment and recovery resources for hundreds of patients. Leading educational events, supporting local agencies, and participating in government initiatives have further solidified UC and UC Health’s role as a stakeholder in this crisis, showcasing how academic health centers are critical to promoting public health.

scholarly journals 1073. The Time is Now for Rapid Initiation of Hepatitis C Virus (HCV) Treatment

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S564-S564
Author(s):  
Colton P Radford ◽  
Paulina Deming ◽  
Carla Walraven
Keyword(s):  
New Mexico ◽  
Task Force ◽  
Clinical Success ◽  
Medical Center ◽  
Academic Medical Center ◽  
Tertiary Care ◽  
Hcv Treatment ◽  
Access To Treatment ◽  
Care Cascade ◽  
Hcv Screening

Abstract Background An estimated 65,000 New Mexicans are infected with HCV, accounting for ~3% of the state’s population with intravenous drug use being the most common risk factor for the acquisition of HCV. In 2020, the US Preventive Service Task Force recommended universal HCV screening for all adults aged 18 to 79 years old. HCV screening requires a two-step process involving a HCV antibody (Ab) test followed by a confirmatory HCV ribonucleic acid (RNA) test to detect active infection. Acute HCV infections are typically asymptomatic leaving many individuals unaware of their diagnosis for years. New Mexico was one of the first states to abandon the requirement for specialist referral, fibrosis staging, and abstinence from substance abuse to facilitate HCV treatment. Despite removal of these barriers, major gaps in access to HCV treatment still persist. The objective was to develop a HCV connect-to-care cascade for the University of New Mexico Hospital (UNMH) to understand the potential barriers preventing patients from receiving appropriate care. Methods This was a retrospective, single center, descriptive study conducted at UNMH, a level 1 trauma, tertiary care academic medical center with 527 beds. All patients with a positive HCV Ab, RNA, or genotype obtained in 2018 were included in this study. There were no exclusions. Results In 2018, over 11,000 unique patients received HCV testing in any form resulting in a total of 14,566 HCV tests being performed. 2018 UNMH Connect-to-Care Cascade Conclusion Of the patients who screened positive, only 61.7% were referred for treatment, representing the largest gap in the cascade. However, once patients were seen in the clinic, 88.5% completed treatment with 100% having sustained virologic response (SVR). With the pan-genotypic HCV treatments having fewer side effects and high clinical success rates, it’s feasible that HCV treatment may no longer require a specialist. Similar to the rapid initiation of antiretrovirals in newly diagnosed HIV patients, where immediate access to treatment within days of diagnosis resulted in improved retention in care, decreased time to viral suppression, and decreased viral transmission, rapid initiation of HCV treatment may be the wave of the future. Disclosures All Authors: No reported disclosures

Report of the ADEA president's task force on the Surgeon General's report on oral health. American Dental Education Association

2000 ◽  
Vol 64 (10) ◽  
pp. 708-714
Author(s):  
PJ Ferrillo ◽  
KB Chance ◽  
RI Garcia ◽  
WE Kerschbaum ◽  
JJ Koelbl ◽  
...  
Keyword(s):  
Oral Health ◽  
Task Force ◽  
Dental Education ◽  
Education Association

Hot Topics: A Report From the Division 4 Task Force on Fluency Services in the Schools

2001 ◽  
Vol 11 (3) ◽  
pp. 6-13
Author(s):  
Lisa Scott-Trautman ◽  
Kristin A. Chmela
Keyword(s):  
Task Force

Entrapment Neuropathies: Electrodiagnostic Criteria

2019 ◽  
Vol 24 (6) ◽  
pp. 12-15
Author(s):  
Jay Blaisdell ◽  
James B. Talmage
Keyword(s):  
Nerve Conduction ◽  
Task Force ◽  
Conduction Block ◽  
Cubital Tunnel Syndrome ◽  
Conduction Delay ◽  
Test Results ◽  
Sixth Edition ◽  
Entrapment Neuropathies ◽  
Axon Loss ◽  
Tunnel Syndrome

Abstract Like the diagnosis-based impairment (DBI) method and the range-of-motion (ROM) method for rating permanent impairment, the approach for rating compression or entrapment neuropathy in the upper extremity (eg, carpal tunnel syndrome [CTS]) is a separate and distinct methodology in the AMA Guides to the Evaluation of Permanent Impairment (AMA Guides), Sixth Edition. Rating entrapment neuropathies is similar to the DBI method because the evaluator uses three grade modifiers (ie, test findings, functional history, and physical evaluation findings), but the way these modifiers are applied is different from that in the DBI method. Notably, the evaluator must have valid nerve conduction test results and cannot diagnose or rate nerve entrapment or compression without them; postoperative nerve conduction studies are not necessary for impairment rating purposes. The AMA Guides, Sixth Edition, uses criteria that match those established by the Normative Data Task Force and endorsed by the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM); evaluators should be aware of updated definitions of normal from AANEM. It is possible that some patients may be diagnosed with carpal or cubital tunnel syndrome for treatment but will not qualify for that diagnosis for impairment rating; evaluating physicians must be familiar with electrodiagnostic test results to interpret them and determine if they confirm to the criteria for conduction delay, conduction block, or axon loss; if this is not the case, the evaluator may use the DBI method with the diagnosis of nonspecific pain.

Sign in / Sign up

Export Citation Format

Share Document